Jasper Therapeutics Announces $30 Million Public Offering

Jasper Therapeutics ( (JSPR) ) has provided an announcement.

On September 18, 2025, Jasper Therapeutics announced the pricing of a $30 million public offering of common stock, pre-funded warrants, and common warrants. The proceeds from this offering are intended to support the advancement of Jasper’s preclinical and clinical development programs of briquilimab in mast-cell driven diseases and for general corporate purposes. Additionally, Jasper provided an update on its ongoing investigation into the confounded efficacy results from the BEACON study in CSU, indicating that the anomalies are not related to drug manufacturing or distribution processes. The investigation is now focusing on clinical site activities, with expected completion in the fourth quarter of 2025.

The most recent analyst rating on (JSPR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Spark’s Take on JSPR Stock

According to Spark, TipRanks’ AI Analyst, JSPR is a Underperform.

Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock’s unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.

To see Spark’s full report on JSPR stock, click here.

More about Jasper Therapeutics

Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.

Average Trading Volume: 627,511

Technical Sentiment Signal: Sell

Current Market Cap: $37.87M

For an in-depth examination of JSPR stock, go to TipRanks’ Overview page.